Diverse Mechanisms of Vemurafenib Resistance in BRAF-Mutant Hairy Cell Leukemia

被引：22
|
作者：
Park, Jae H. [1 ]
Chung, Stephen S. [1 ]
Durham, Benjamin [2 ]
Chung, Young Rock [3 ]
Scott, Sasinya [2 ]
Getta, Bartlomiej [2 ]
Kim, Eunhee [2 ]
Saven, Alan [4 ]
Stone, Richard M. [5 ]
Rai, Kanti R. [6 ]
Grever, Michael R. [7 ]
Altman, Jessica K. [8 ]
Rosen, Neal [9 ]
Levine, Ross L. [2 ]
Berger, Michael [10 ]
Tallman, Martin S. [1 ]
Abdel-Wahab, Omar [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA
[4] Scripps Hlth, La Jolla, CA USA
[5] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[6] North Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA
[7] Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
[8] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[9] Mem Sloan Kettering Canc Ctr, Pharmacol, New York, NY 10021 USA
[10] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.682.682
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
    Jang, S.
    Atkins, M. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (01) : 24 - 31
  • [12] A Novel Dendritic Cell Vaccine Targeting Mutated BRAF Overcomes Vemurafenib Resistance and Synergistically Improves Survival in BRAF-Mutant Murine Melanoma
    Datta, J.
    Cintolo-Gonzalez, J. A.
    Ellingsworth, C.
    Xu, S.
    Lowenfeld, L.
    Berk, E.
    Somasundaram, R.
    Czerniecki, B. J.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S31 - S31
  • [13] Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
    Yang, Hong
    Higgins, Brian
    Kolinsky, Kenneth
    Packman, Kathryn
    Bradley, William D.
    Lee, Richard J.
    Schostack, Kathleen
    Simcox, Mary Ellen
    Kopetz, Scott
    Heimbrook, David
    Lestini, Brian
    Bollag, Gideon
    Su, Fei
    CANCER RESEARCH, 2012, 72 (03) : 779 - 789
  • [14] Resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma
    Patel, Hima
    Yacoub, Nour
    Garrett, Joan T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB43 - AB43
  • [15] Exquisite sensitivity of refractory hairy-cell leukemia to BRAF inhibition with Vemurafenib
    Dietrich, S.
    Huellein, J.
    Hundemer, M.
    Lehners, N.
    Meissner, J.
    Jethwa, A.
    Acker, T.
    Galanov, B.
    Andrulis, M.
    Schulte, C.
    Mandel, T.
    Dreger, P.
    Froehling, S.
    von Kalle, C.
    Ho, A. D.
    Glimm, H.
    Zenz, T.
    ONKOLOGIE, 2012, 35 : 246 - 247
  • [16] BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
    Spagnolo, Francesco
    Ghiorzo, Paola
    Orgiano, Laura
    Pastorino, Lorenza
    Picasso, Virginia
    Tornari, Elena
    Ottaviano, Vincenzo
    Queirolo, Paola
    ONCOTARGETS AND THERAPY, 2015, 8 : 157 - 168
  • [17] Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review
    Tangella, Lokeswari P.
    Clark, Michael E.
    Gray, Elin S.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2021, 1865 (01):
  • [18] Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.
    Bai, Xue
    Si, Lu
    Chi, Zhihong
    Sheng, Xinan
    Cui, Chuanliang
    Kong, Yan
    Dai, Jie
    Mao, Li Li
    Wang, Xuan
    Li, Si Ming
    Tang, Bixia
    Lian, Bin
    Zhou, Li
    Yan, Xieqiao
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [19] A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
    Harding, James J.
    Catalanotti, Federica
    Munhoz, Rodrigo R.
    Cheng, Donavan T.
    Yaqubie, Amin
    Kelly, Nicole
    Mcdermott, Gregory C.
    Kersellius, Romona
    Merghoub, Taha
    Lacouture, Mario E.
    Carvajal, Richard D.
    Panageas, Katherine S.
    Berger, Michael F.
    Rosen, Neal
    Solit, David B.
    Chapman, Paul B.
    ONCOLOGIST, 2015, 20 (07): : 789 - 797
  • [20] Overcoming BRAF/MEK resistance using vemurafenib with crizotinib or sorafenib in patients with BRAF-mutant advanced cancers: phase I study
    Kato, Shumei
    Naing, Aung
    Falchook, Gerald
    Holley, Veronica R.
    Velez-Bravo, Vivianne M.
    Patel, Sapna
    Zinner, Ralph G.
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia M.
    Hong, David S.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Janku, Filip
    CANCER RESEARCH, 2015, 75
12345